Loading clinical trials...
Loading clinical trials...
To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Northside Hospital, Inc.
NCT07104799 · Myelofibrosis, Hematopoietic Cell Transplantation (HCT)
NCT06705062 · Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease
NCT07140770 · Physical Activity, Sleep, and more
NCT07257419 · Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, and more
NCT03394365 · Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, and more
Northside Hospital
Atlanta, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions